766 related articles for article (PubMed ID: 11318778)
1. Effects of androgen deficiency and replacement on prostate zonal volumes.
Jin B; Conway AJ; Handelsman DJ
Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
[TBL] [Abstract][Full Text] [Related]
2. Effects of liver disease and transplantation on the human prostate.
Jin B; McCaughan GW; Handelsman DJ
J Androl; 1999; 20(4):559-65. PubMed ID: 10452601
[TBL] [Abstract][Full Text] [Related]
3. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
4. The effects of chronic high dose androgen or estrogen treatment on the human prostate [corrected].
Jin B; Turner L; Walters WA; Handelsman DJ
J Clin Endocrinol Metab; 1996 Dec; 81(12):4290-5. PubMed ID: 8954029
[TBL] [Abstract][Full Text] [Related]
5. Age, genetic, and nongenetic factors influencing variation in serum sex steroids and zonal volumes of the prostate and benign prostatic hyperplasia in twins.
Meikle AW; Stephenson RA; Lewis CM; Wiebke GA; Middleton RG
Prostate; 1997 Oct; 33(2):105-11. PubMed ID: 9316651
[TBL] [Abstract][Full Text] [Related]
6. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
[TBL] [Abstract][Full Text] [Related]
7. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester.
Behre HM; Nieschlag E
J Clin Endocrinol Metab; 1992 Nov; 75(5):1204-10. PubMed ID: 1430080
[TBL] [Abstract][Full Text] [Related]
8. Growth and development during early manhood as determinants of prostate size in later life.
Zhuang TN; Ly LP; Cumming RG; Handelsman DJ
J Clin Endocrinol Metab; 2005 Nov; 90(11):6055-63. PubMed ID: 16131576
[TBL] [Abstract][Full Text] [Related]
9. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls.
Behre HM; Bohmeyer J; Nieschlag E
Clin Endocrinol (Oxf); 1994 Mar; 40(3):341-9. PubMed ID: 7514512
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
11. Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients.
Colao A; Spiezia S; Di Somma C; Marzullo P; Cerbone G; Pivonello R; Faggiano A; Lombardi G
Eur J Endocrinol; 2000 Jul; 143(1):61-9. PubMed ID: 10870032
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial.
Idan A; Griffiths KA; Harwood DT; Seibel MJ; Turner L; Conway AJ; Handelsman DJ
Ann Intern Med; 2010 Nov; 153(10):621-32. PubMed ID: 21079217
[TBL] [Abstract][Full Text] [Related]
14. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin S; Brito JP; Cunningham GR; Hayes FJ; Hodis HN; Matsumoto AM; Snyder PJ; Swerdloff RS; Wu FC; Yialamas MA
J Clin Endocrinol Metab; 2018 May; 103(5):1715-1744. PubMed ID: 29562364
[TBL] [Abstract][Full Text] [Related]
15. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men.
Burris AS; Banks SM; Carter CS; Davidson JM; Sherins RJ
J Androl; 1992; 13(4):297-304. PubMed ID: 1399830
[TBL] [Abstract][Full Text] [Related]
16. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system.
Meikle AW; Arver S; Dobs AS; Adolfsson J; Sanders SW; Middleton RG; Stephenson RA; Hoover DR; Rajaram L; Mazer NA
Urology; 1997 Feb; 49(2):191-6. PubMed ID: 9037280
[TBL] [Abstract][Full Text] [Related]
17. Effects of testosterone replacement in hypogonadal men.
Snyder PJ; Peachey H; Berlin JA; Hannoush P; Haddad G; Dlewati A; Santanna J; Loh L; Lenrow DA; Holmes JH; Kapoor SC; Atkinson LE; Strom BL
J Clin Endocrinol Metab; 2000 Aug; 85(8):2670-7. PubMed ID: 10946864
[TBL] [Abstract][Full Text] [Related]
18. Volume change of the prostate and seminal vesicles in male hypogonadism after androgen replacement therapy.
Sasagawa I; Nakada T; Kazama T; Satomi S; Terada T; Katayama T
Int Urol Nephrol; 1990; 22(3):279-84. PubMed ID: 2210985
[TBL] [Abstract][Full Text] [Related]
19. Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins.
Meikle AW; Stephenson RA; Lewis CM; Middleton RG
J Clin Endocrinol Metab; 1997 Feb; 82(2):571-5. PubMed ID: 9024256
[TBL] [Abstract][Full Text] [Related]
20. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
